Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Nov 28;22(1):126.
doi: 10.1186/s12981-025-00795-9.

Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I

Charlotte-Paige Rolle  1 , Michelle L D'Antoni  2 , Roberto Corales  3 , Andrea Marongiu  4 , Joshua Gruber  3 , Tanya Schreibman  5 , Dionne Bell  6 , Chiu-Bin Hsiao  7 , Indira Brar  8
Affiliations
Observational Study

Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I

Charlotte-Paige Rolle et al. AIDS Res Ther. .

Abstract

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is indicated for people with HIV who are virologically suppressed, including those with M184V/I. Data on B/F/TAF effectiveness during viremia with M184V/I are limited. This observational study retrospectively collected clinical/demographic data from adults with viremia and M184V/I receiving B/F/TAF or alternate antiretroviral therapy (ART). Virologic suppression at 3 and ≥ 6 months was evaluated. For participants with data, 5/5 (100%) and 7/8 (88%) on B/F/TAF and 4/6 (67%) and 7/10 (70%) on alternate ART achieved virologic suppression at 3 and ≥ 6 months, respectively. Virologic suppression was achieved in most people with HIV who were viremic with M184V/I on B/F/TAF, as with alternate ART.

Keywords: Effectiveness of B/F/TAF; M184V/I; Viremia.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The protocol was approved by local institutional review boards. The study was conducted in accordance with the European Medicines Agency – Guideline on Good Pharmacovigilance Practices Module VIII – Post-Authorization Safety Studies. Consent for publication: Not applicable. Competing interests: C-PR reports research grants paid to their institution from Gilead Sciences, Inc., MSD, and ViiV Healthcare, payment or honoraria for speakers bureaus from Gilead Sciences, Inc. and ViiV Healthcare, and participation on an advisory board for ViiV Healthcare. DB reports payment or honoraria for speakers bureaus and support for attending speakers training/bureau from Gilead Sciences, Inc. IB reports grants or contracts from Gilead Sciences, Inc., Merck, and ViiV Healthcare, consulting fees for advisory boards from Gilead Sciences, Inc., and support for attending speakers bureau training and payment or honoraria for speakers bureaus from Gilead Sciences, Inc. and ViiV Healthcare. MLD, RC, AM, and JG are employees and shareholders of Gilead Sciences, Inc. TS and C-BH declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Virologic outcomes at 3 and ≥ 6 months after treatment initiation/switch. Only participants with available data are shown. ART, antiretroviral therapy; ATV, atazanavir; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; c, cobicistat; DRV, darunavir; DTG, dolutegravir. aOne participant on DTG + ATV with 75–84% adherence had viral load 7830 copies/mL at 3 months and subsequently resuppressed at 6 months (viral load 30 copies/mL); 1 participant on DRV with 100% adherence had viral load 51 copies/mL at 3 months and 913 copies/mL at 14 months (≥ 6-month timepoint). bOne participant on B/F/TAF with 75–84% adherence had no data at 3 months and viral load 328 copies/mL at 6 months; this participant discontinued treatment due to reported lack of efficacy and subsequently achieved virologic suppression on DRV + DTG. cOne participant on DTG + cDRV/F/TAF with 50–74% adherence had no data at 3 months and viral load 625 copies/mL at 6 months; 1 participant on cDRV/F/TAF with a reported adherence range of 0–24% was virologically suppressed at 3 months and had viral load 6642 copies/mL at 6 months
See this image and copyright information in PMC

References

    1. World Health Organization. HIV drug resistance. 2024. https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance. Accessed 13 Jun 2025.
    1. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis. 2013;208:1102–12. - DOI - PubMed
    1. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother. 2011;66:2346–9. - DOI - PubMed
    1. Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B, et al. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 seroconverter study cohort. PLoS ONE. 2019;14:e0209605. - DOI - PMC - PubMed
    1. Kagan RM, Baxter JD, Kim T, Marlowe EM. HIV-1 drug resistance trends in the era of modern antiretrovirals: 2018–2024. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 9–12 Mar 2025; San Francisco, CA. Poster 730. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources